-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $285

Benzinga·07/14/2026 11:33:39
Listen to the news
Wells Fargo analyst Mohit Bansal maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $265 to $285.